Cipla Limited's Scheme of Amalgamation with Inzpera Healthsciences approved by NCLT
Cipla · Pharmaceuticals & Biotechnology
Key highlights
- NCLT Mumbai Bench approved the Scheme of Amalgamation of Inzpera Healthsciences Limited (Transferor) with Cipla Limited (Transferee) on 18 August 2026.
- The Transferor is a wholly owned subsidiary of Cipla Limited; amalgamation effective from 1 April 2026.
- The order includes directions for notices to authorities and filing of documents related to guarantees, litigation, and letters of credit.
Why it's rated notable: The NCLT order approves the amalgamation of a wholly-owned subsidiary into the Company, with no value or share issue stated, so the level is capped at medium.
Original filing
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Cipla
- Dividend / buyback / bonusMajor development· Adverse for the businessCipla announces Q4FY26 and FY26 audited results, dividend, and earnings call details
- Acquisition / mergerNotableCipla Ltd approves leadership changes, USD 100M investment, and subsidiary merger
- Acquisition / mergerNotableCipla Ltd announces board changes, investment in Cipla (EU) Ltd, and merger approval
Other other filings this fortnight
- Kesoram Industries gets Rs. 5,989.35 Lakhs arbitral award against Kesoram Textile Mills
- Sagar Cements receives no adverse observation letters for amalgamation scheme
- Kalpataru Projects International Ltd reports unaudited Q2 and H1 FY27 financial results
- Urja Global Ltd appoints new CEO and CFO, announces Q2 FY26 financial results
- Lloyds Enterprises Ltd reports unaudited financial results for Q2 FY 2026-27
- Urja Global Limited announces Q2 FY 2026-27 results and key managerial appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.